Ignite Creation Date:
2025-12-25 @ 4:50 AM
Ignite Modification Date:
2026-01-28 @ 5:18 PM
Study NCT ID:
NCT00440518
Status:
COMPLETED
Last Update Posted:
2018-07-17
First Post:
2007-02-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
Sponsor:
UCB Pharma
Organization:
Study Overview
Official Title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03559673
Has Expanded Access, NCT# Status:
NO_LONGER_AVAILABLE
Acronym:
SP906
Brief Summary:
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
Detailed Description:
This study is for subjects who have been diagnosed with migraine for at least one year and who are currently taking an effective abortive medication(s).
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: